Stock listing

OTC:ZVSA ZyVersa Therapeutics, Inc. Stock

Follow ZyVersa Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · OTC:ZVSA

$0.0001 USD 0.0000 (0.0%)

Close on Nov 20, 2026

Past year -99.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.0001 – $0.0001 USDNov 20, 2026
Volume
3,400 sharesNov 20, 2026
Market cap
$810 USDAt the close on Nov 20, 2026 · price × 8.10M shares outstanding
52-week range
$0.0001 – $0.3000 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$672 USDMedian day 2,195 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
ZyVersa Therapeutics, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:ZVSA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00010.00000.0%$0.0001$0.0001$0.00013,400
$0.00010.00000.0%$0.0001$0.0001$0.0001100
$0.00010.00000.0%$0.0001$0.0001$0.00011,077
$0.00010.00000.0%$0.0001$0.0001$0.00013,676
$0.00010.00000.0%$0.0001$0.0001$0.00011,184
$0.0001-0.0009-90.0%$0.0001$0.0001$0.00011,730
$0.00100.00000.0%$0.0010$0.0010$0.0010150
$0.00100.00000.0%$0.0004$0.0010$0.00043,748
$0.00100.00000.0%$0.0010$0.0010$0.0010743
$0.00100.00000.0%$0.0010$0.0010$0.0010861
$0.0010+0.0008+400.0%$0.0005$0.0010$0.0005889
$0.0002-0.0478-99.6%$0.0002$0.0002$0.0002695
$0.0480+0.0035+7.9%$0.0455$0.0500$0.0415103,219
$0.0445-0.0350-44.0%$0.0722$0.0722$0.0389216,164
$0.0795-0.0004-0.5%$0.0800$0.0800$0.07952,371
$0.0799+0.0001+0.1%$0.0798$0.0799$0.0798360
$0.0798+0.0003+0.4%$0.0798$0.0798$0.0798571
$0.0795-0.0028-3.4%$0.0850$0.0850$0.07955,058
$0.0823+0.0028+3.5%$0.0990$0.0990$0.08232,399
$0.0795-0.0005-0.6%$0.0801$0.1018$0.079516,814
$0.08000.00000.0%$0.0802$0.0802$0.080016,725
$0.0800-0.0222-21.7%$0.0990$0.1020$0.079551,333
$0.1022-0.0048-4.5%$0.1022$0.1022$0.1022159
$0.1070+0.0040+3.9%$0.0990$0.1070$0.09901,451
$0.1030+0.0040+4.0%$0.0990$0.1149$0.099011,664
$0.0990-0.0051-4.9%$0.0990$0.0990$0.0990281
$0.1041+0.0041+4.1%$0.0990$0.1041$0.09901,016
$0.1000+0.0010+1.0%$0.1000$0.1000$0.10001,051
$0.0990-0.0144-12.7%$0.0990$0.0990$0.0990349
$0.1134+0.0144+14.5%$0.1122$0.1134$0.1122484
$0.09900.00000.0%$0.0990$0.1149$0.09902,733
$0.09900.00000.0%$0.1047$0.1047$0.09903,821
$0.0990-0.0080-7.5%$0.0990$0.0990$0.0990515
$0.1070+0.0080+8.1%$0.1070$0.1070$0.1070141
$0.0990-0.0010-1.0%$0.0992$0.0992$0.099014,517
$0.1000+0.0010+1.0%$0.0992$0.1149$0.099015,912
$0.0990-0.0002-0.2%$0.0990$0.0990$0.09905,651
$0.0992-0.0038-3.7%$0.0990$0.0992$0.0990960
$0.1030+0.0038+3.8%$0.0990$0.1030$0.09902,528
$0.09920.00000.0%$0.0990$0.1071$0.09905,645
$0.0992+0.0002+0.2%$0.0990$0.1039$0.09902,295
$0.09900.00000.0%$0.0990$0.0990$0.0990252
$0.0990-0.0060-5.7%$0.1071$0.1140$0.09908,206
$0.1050+0.0060+6.1%$0.1090$0.1090$0.10505,213
$0.09900.00000.0%$0.1155$0.1155$0.09902,080
$0.0990-0.0005-0.5%$0.1160$0.1160$0.099012,560
$0.09950.00000.0%$0.1100$0.1100$0.09951,261
$0.0995-0.0037-3.6%$0.1036$0.1036$0.09952,095
$0.1032-0.0068-6.2%$0.0990$0.1075$0.09902,610
$0.1100+0.0110+11.1%$0.1100$0.1170$0.09907,027

Splits

2 splits since 2023 · OTC:ZVSA · every price before a split is adjusted for it

DayRatioWhat
1-for-10Consolidation
1-for-35Consolidation
Ticker
OTC:ZVSA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

ZyVersa Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
Decks
2 decks · latest 2026

Valuation

Statements: 4 quarters to Mar 31, 2026 · price Nov 20, 2026

Enterprise value
$1.20B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
-0.56

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
ZyVersa Therapeutics, Inc. · OTC:ZVSAUS$810US$1.20Bn/an/an/an/an/an/a-0.56
Vaxil Bio Ltd. · TSXV:VXLUS$319,500−US$4,0701.2×n/an/a0.4×n/a0.0×-0.16
Chimeric Therapeutics Limited · ASX:CHMUS$292,816−US$220,193n/a−0.1×n/a0.2×−262.8%2.5×n/a
CERo Therapeutics Holdings, Inc. · OTC:CEROUS$265,035−US$190,890n/an/an/an/an/an/a1.47
CDT Equity Inc. · NASDAQ:CDTUS$234,109−US$1.49Mn/an/an/a0.0×n/a0.0×1.14
GlucoTrack, Inc. · NASDAQ:GCTKUS$217,049−US$887,951n/an/an/an/an/an/a1.73
Regen BioPharma, Inc. · OTC:RGBPUS$167,528US$167,289n/a0.7×n/an/a−501.4%n/a1.20
CNBX Pharmaceuticals Inc. · OTC:CNBXUS$160,577US$151,090n/an/an/an/an/an/a1.78
Fifty 1 Labs Inc. · OTC:FITYUS$118,532US$282,021n/a6,000×n/an/an/an/a-1.17
GB Sciences, Inc. · OTC:GBLXUS$81,414US$2.07Mn/an/an/an/an/an/a-0.46
Lyra Therapeutics, Inc. · OTC:LYRAUS$53,246US$14.42Mn/a36.2×n/an/an/an/a0.67
Median of the othersUS$192,289US$73,5101.2×18.5×0.2×−382.1%0.0×1.14

Team and board

Officers

OfficerRole
James SapirsteinChairman and CEO – 8 Prime Biosciences
Stephen C. GloverCo-founder, Chairman, CEO, and President
Peter WolfeChief Financial Officer
Karen CashmereChief Commercial Officer

Board

DirectorRole
James SapirsteinChairman and CEO – 8 Prime Biosciences
Stephen C. GloverCo-founder, Chairman, CEO, and President
Gregory G. FreitagPrincipal of FreiMc

Events

QuarterResultsShare move
Q1 2026May 19, 2026−8.0%
Q3 2025Nov 19, 20250.0%
Q2 2025Aug 13, 2025+7.3%
Q1 2025May 12, 2025−1.8%
Q4 2024Mar 27, 2025−17.8%
Q3 2024Nov 14, 2024 · Before open−9.6%
Q2 2024Aug 9, 2024 · After close−5.6%
Q1 2024May 15, 2024 · Before open−6.6%
Q4 2023Mar 25, 2024 · Before open−2.0%
Q3 2023Nov 14, 2023 · After close−1.1%
All 16 quarters
QuarterResultsShare move
Q2 2023Aug 21, 2023 · After close−6.5%
Q1 2023Apr 12, 2023+4.7%
Q3 2022Nov 14, 2022+0.4%
Q2 2022Aug 15, 20220.0%
Q1 2022Apr 15, 2022
Q3 2021Dec 22, 2021

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (2026)Investor deck18 slides2026
SPAC Merger (July 2022)SPAC merger51 slidesJul 22, 2022

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue000000
Cost of revenue6.93K10.4K10.4K10.4K10.4K
Gross profit-6.93K-10.4K-10.4K-10.4K-10.4K
Research and development1.11M1.78M3.21M5.41M2.12M6.47M
Selling, general and administrative5.73B7.36B11.2B7.61M5.58M5.36M
Operating income-25.5M-9.14M-107.8M-13.8M-7.70M-11.8M
Depreciation and amortization06.93K10.4K9.87K10.4K10.4K
EBITDA-25.5M-9.13M-107.7M-13.8M-7.69M-11.8M
Interest expense513.2K269.9K457.0K427.5K821.4K516.5K
Income before tax-25.8M-9.41M-107.8M-14.9M-8.08M-12.7M
Income tax-851.7K6.75K-9.46M-745.0K821.4K516.5K
Net income-25.0M-9.41M-98.3M-14.0M-8.08M-12.7M
Earnings per share, basic-4.18-8.48-1,089.70-541.38-173.66-272.45
Earnings per share, diluted-4.18-8.48-1,089.70

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents101.8K1.53M3.14M5.90M328.6K174.7K
Short-term investments1.53B
Current assets463.5K1.72M3.35M6.36M811.8K339.1K
Property, plant and equipment6.93K115.7K27.7K38.1K
Goodwill011.9M0
Total assets463.5K20.6M22.1M118.5M1.13M685.6K
Accounts payable10.1M9.34M8.43M6.03M2.00M2.31M
Current liabilities12.9M11.2M10.2M8.19M13.6M7.56M
Long-term debt1.69M
Total debt8.66K108.8K9.15M3.82M
Total liabilities12.9M12.1M11.0M18.5M13.6M9.24M
Shareholders' equity-12.4M8.52M11.1M100.0M-12.5M-8.56M
Shares outstanding8.10M2.51M402.2K25.9K46.6K46.6K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-5.11M-7.52M-8.72M-4.89M-5.08M-5.11M
Capital spending0-3-1000
Free cash flow-5.11M-7.56M-8.72M-1.49M-5.08M-5.11M
Cash from financing3.69M5.91M5.96M1.87M5.23M4.56M
Share buybacks0-10.7M0
Change in cash-1.43M-1.61M-2.76M5.57M153.9K-549.8K

Open Financials

Cap table

Built by 6ix from ZyVersa Therapeutics, Inc.’s releases

Common shares
8,095,921
Fully diluted
8,095,921

Fully diluted

LineShares
Common shares8,095,921

Share count over time

CountShares
Nov 22, 20268,095,921

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James Sapirstein
Other companies: INmune Bio Inc. (Director · Since at least Sep 8, 2026); Cocrystal Pharma, Inc. (Chief Executive Officer · Since at least Jun 3, 2026); Onconetix, Inc. (Director · Feb 23, 2022 – Sep 26, 2024 · Past); Blue Water Acquisition Corp (Director · Dec 15, 2020 – Dec 15, 2020 · Past); Marizyme, Inc. (Interim CEO, Director · Sep 10, 2020 – Mar 5, 2021 · Past); GridAI Technologies Corp. (Chairman and CEO, Director · Oct 8, 2019 – Jul 2, 2024 · Past); Lunai Bioworks Inc. (Director · Mar 6, 2018 – Jun 25, 2024 · Past); Hepion Pharmaceuticals, Inc. (Chief Executive Officer, Director · Jan 3, 2018 – Jan 3, 2018 · Past); RespireRx Pharmaceuticals Inc (Director · Dec 9, 2017 – Dec 9, 2017 · Past)
Director · Since at least Jan 5, 2023
Daniel O’Connor
Other companies: DiaMedica Therapeutics Inc. (Director · Since at least Feb 20, 2025); Ambrx Biopharma Inc. (President and CEO, Director · Jan 1, 2023 – Mar 7, 2024 · Past)
Director · Dec 20, 2021 – Dec 12, 2022 · Past
David Briones
Other companies: Hoth Therapeutics, Inc. (Chief Financial Officer · Since at least Mar 5, 2019); Unique Logistics International Inc (Director · Sep 6, 2022 – May 14, 2025 · Past)
Chief Financial Officer, Director · Dec 20, 2021 – Jan 6, 2022 · Past
Robert G Finizio
Other companies: TherapeuticsMD, Inc. (CEO, Director · Feb 28, 2019 – Jul 1, 2021 · Past)
Director · Since at least Dec 12, 2022
Gregory G. FreitagPrincipal of FreiMc · Since at least Nov 5, 2026
Karen CashmereChief Commercial Officer · Since at least Nov 4, 2026
Min-Chul ParkDirector · Since at least Jul 11, 2025
Nicholas A LaBella JrChief Scientific Officer · Dec 12, 2022 – Dec 12, 2022 · Past
Pablo A GuzmanChief Medical Officer · Since at least Jul 11, 2025
Peter WolfeChief Financial Officer · Since at least Jul 18, 2024
All 11 people
PersonSeat
Stephen C. GloverCo-founder, Chairman, CEO, and President · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about ZyVersa Therapeutics, Inc.